Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 27;59(1):2101058.
doi: 10.1183/13993003.01058-2021. Print 2022 Jan.

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: clinical characteristics and progression to carcinoid tumour

Thomas Yang Sun  1 , Grace Hwang  1 , Danielle Pancirer  1 , Kathleen Hornbacker  1 , Alberto Codima  1 , Natalie S Lui  2 , Rishi Raj  3 , Pamela Kunz  1   4 , Sukhmani K Padda  5   6
Affiliations

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: clinical characteristics and progression to carcinoid tumour

Thomas Yang Sun et al. Eur Respir J. .

Abstract

DIPNECH is a rare disease that is often misdiagnosed. In this study, it primarily affected elderly white women who were non-smokers. Lung nodules could slowly progress over years to carcinoid tumours. Average growth rate per nodule was 0.8 mm per year. https://bit.ly/3q1HD1k

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: T.Y. Sun has nothing to disclose. Conflict of interest: G. Hwang has nothing to disclose. Conflict of interest: D. Pancirer has nothing to disclose. Conflict of interest: K. Hornbacker has nothing to disclose. Conflict of interest: A. Codima has nothing to disclose. Conflict of interest: N.S. Lui reports research funding from the Intuitive Foundation and Auspex Diagnostics. Conflict of interest: R. Raj has nothing to disclose. Conflict of interest: P. Kunz has nothing to disclose. Conflict of interest: S.K. Padda reports research funding from Epicentrx, Bayer and Boehringer Ingelheim, and served on the advisory boards of Blueprint, AstraZeneca and G1 Therapeutics.

References

    1. Benson REC, Rosado-de-Christenson ML, Martínez-Jiménez S, et al. . Spectrum of pulmonary neuroendocrine proliferations and neoplasms. Radiographics 2013; 33: 1631–1649. doi:10.1148/rg.336135506 - DOI - PubMed
    1. WHO Classification of Tumours Editorial Board . Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. In: WHO Classification of Tumours. 5th Edn. Lyon, International Agency for Research on Cancer, 2021.
    1. Mengoli MC, Rossi G, Cavazza A, et al. . Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) syndrome and carcinoid tumors with/without NECH: a clinicopathologic, radiologic, and immunomolecular comparison study. Am J Surg Pathol 2018; 42: 646–655. doi:10.1097/PAS.0000000000001033 - DOI - PubMed
    1. Almquist DR, Sonbol MB, Ross HJ, et al. . Clinical characteristics of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: a retrospective analysis. Chest 2020; 14: 432–434. doi:10.1016/j.chest.2020.08.012 - DOI - PubMed
    1. Sazonova O, Manem V, Béland C, et al. . Development and validation of diffuse idiopathic pulmonary neuroendocrine hyperplasia diagnostic criteria. JTO Clin Res Rep 2020; 1: 100078. doi:10.1016/j.jtocrr.2020.100078 - DOI - PMC - PubMed

Publication types